Welcome to our dedicated page for Enochian Biosciences news (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences stock.
Enochian Biosciences, Inc. (ENOB) is a pioneering biopharmaceutical company headquartered in Los Angeles, California. Formerly known as Dandrit Biotech USA Inc., Enochian focuses on developing and commercializing groundbreaking therapies aimed at transforming immunotherapy treatments for HIV/AIDS and cancer.
The company's leading candidate, ENO-1001, is in the pre-Investigational New Drug (pre-IND) stage and has potential as a sterilizing cure for HIV/AIDS. In addition to ENO-1001, Enochian is working on ENO-2001, an HIV vaccine currently in the preclinical stage. The company is also focusing on innovative compounds such as ENO-4001 (a phase three asset), ENO-4002, ENO-5001, and ENO-3001 for the prevention of relapse in colon cancer patients.
Enochian Biosciences has recently faced a significant event where their Annual Meeting required adjournment due to the lack of a quorum. The meeting has been rescheduled to July 21, 2023, at 12:00 p.m. (Eastern Time). The company continues to solicit votes from its stockholders to meet the required quorum. Valid proxies and votes already submitted will still be effective unless revoked, and the company encourages all eligible stockholders to participate.
Enochian Biosciences operates with a clear focus on research and development, continually working on their clinical trials and product development activities. The company is actively engaged in securing regulatory approvals for its products and is strategically positioned for potential future growth. Investors are advised to stay updated with the company's latest developments and filings with the United States Securities and Exchange Commission (SEC).
For more information, stockholders and interested parties can access the company's proxy statement and annual reports, or attend the virtual Annual Meeting.
Enochian BioSciences, Inc. (NASDAQ: ENOB) announced a collaboration with Dr. Anahid Jewett to tackle pancreatic cancer, utilizing innovative genetic modifications in dendritic cells. Dr. Serhat Gumrukçu presented promising lab results that suggest potential efficacy in treating glioblastoma, highlighted by a case where a patient remained tumor-free for two years post-treatment. The company aims to progress from laboratory results to animal models and eventually human trials. CEO Dr. Mark Dybul expressed enthusiasm about this breakthrough partnership and its implications for future cancer therapies.
Enochian BioSciences (NASDAQ: ENOB) is moving closer to submitting an Investigational New Drug (IND) application following favorable comments from the FDA. The firm completed a Pre-IND process, encouraged by results from a case study involving a 54-year-old HIV patient who managed to control their viral load off antiretroviral therapy (ART) for a full year using a novel treatment developed by the Seraph Research Institute. This treatment employs Natural Killer and Gamma Delta T-cells and may offer new hope for effective HIV management.
Enochian BioSciences (NASDAQ: ENOB) announced the resignation of Dr. Peter Piot as Chairperson of the Respiratory Diseases Scientific Advisory Board due to his advisory role with a major governmental organization on COVID-19. Dr. Piot expressed his continued admiration for Enochian's innovative science and pipeline potential but cited a conflict of interest as the reason for his departure. Enochian BioSciences focuses on gene-modified therapies for infectious diseases and cancer, with applications for various conditions including HIV/AIDS and Influenza.
Enochian BioSciences (NASDAQ: ENOB) announced a presentation at the H.C. Wainwright Global Life Sciences Conference scheduled for October 13, 2021. CEO Dr. Mark Dybul will participate in a Fireside Chat focusing on innovative treatments for Hepatitis B. The event aims to highlight the company’s approach to developing gene-modified cellular and immune therapies for various infectious diseases and cancers. The discussion will be available live for attendees and can also be accessed later on the company's website.
Enochian BioSciences announces completion of its Pre-Investigational New Drug (IND) process, following helpful feedback from the FDA’s CBER. This feedback outlines a clear path towards a successful IND application for the innovative ENOB-HB-01 therapy, which employs a 'Hijack RNA' strategy to eliminate HBV-infected liver cells. With nearly 350 million individuals affected globally by chronic liver disease from HBV, the company aims to develop impactful treatments. The FDA’s insights are also expected to expedite the development of other potential therapeutic products.
Enochian BioSciences announced its participation in the H.C. Wainwright Global Life Sciences Conference on September 13, 2021. CEO Dr. Mark Dybul will present the company's advancements in gene-modified cellular and immune therapies targeting infectious diseases and cancer, including platforms for HIV, Hepatitis B, influenza, and coronavirus. The presentation will be accessible on-demand starting at 7:00 AM Eastern on the same day via the Enochian BioSciences website.
Enochian BioSciences (NASDAQ: ENOB) announced the formation of a Scientific Advisory Board (SAB) to advance inhaled treatments targeting SARS-CoV-2 and Influenza variants. The SAB includes prominent experts like Dr. Peter Piot, Chairperson, and Dr. Richard Whitley, both pivotal in global health research. Their involvement is expected to enhance the company's potential to develop therapies that could significantly impact COVID-19 management and future pandemic preparedness. CEO Mark Dybul emphasized the crucial expertise the SAB brings to accelerate research and development efforts.
Enochian BioSciences (NASDAQ: ENOB) has appointed Dr. Anna Suk-Fong Lok to its Scientific Advisory Board. Dr. Lok, a leading clinical researcher and former President of the American Association for the Study of Liver Diseases, will aid in the development of a potential cure for Hepatitis B Virus (HBV), affecting 350 million people globally. Enochian is progressing with its Pre-Investigational New Drug application, aiming to advance through regulatory processes. Dr. Lok's involvement is expected to enhance the company's research capabilities in advancing treatments for HBV.
Enochian BioSciences, Inc. has appointed Dr. Mark Dybul as the new CEO, effective immediately. Dr. Dybul, a renowned expert in public health, previously served as Executive Vice-Chair of the Board since January 2019. He is recognized for leading successful global health initiatives, including the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), which grew from $500 million to $6.5 billion annually. Under his leadership, Enochian aims to expedite the development of treatments for Hepatitis B, HIV, and respiratory viruses like COVID-19.
Enochian BioSciences, Inc. (NASDAQ: ENOB) announced that the FDA has accepted its Pre-IND request for a potential cure for hepatitis B virus (HBV) infection. This progress follows promising data from a proof-of-concept study in chimeric mice. Dr. Mark Dybul and Dr. Carol Brosgart expressed optimism about the novel Hijack RNA mechanism, highlighting its potential against HBV and other viruses, including COVID-19 and HIV. The company aims to develop gene-modified therapies to address serious diseases affecting millions globally.
FAQ
What is the market cap of Enochian Biosciences (ENOB)?
What does Enochian Biosciences do?
Where is Enochian Biosciences headquartered?
What is ENO-1001?
What stage is ENO-2001 in?
What are some other compounds Enochian is working on?
When is the rescheduled Annual Meeting?
How can stockholders vote for the proposals?
Who is helping Enochian with the voting process?
Where can I find the proxy statement and annual reports?
How can I attend the virtual Annual Meeting?
